Pinnacle Wealth Planning Services Inc. Sells 272 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Pinnacle Wealth Planning Services Inc. trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 19.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 1,146 shares of the medical research company’s stock after selling 272 shares during the quarter. Pinnacle Wealth Planning Services Inc.’s holdings in IQVIA were worth $225,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Capital Performance Advisors LLP acquired a new position in IQVIA in the third quarter valued at about $27,000. Avior Wealth Management LLC raised its position in shares of IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares in the last quarter. Synergy Asset Management LLC bought a new stake in shares of IQVIA during the 4th quarter worth approximately $33,000. Assetmark Inc. boosted its position in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares in the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in IQVIA in the third quarter valued at approximately $57,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on IQV. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Tuesday. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. JPMorgan Chase & Co. decreased their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, Stifel Nicolaus decreased their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Trading Up 3.4 %

Shares of IQV stock opened at $191.69 on Friday. The stock has a 50-day moving average of $197.79 and a 200-day moving average of $213.11. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market cap of $33.80 billion, a price-to-earnings ratio of 25.56, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.